The Acute Porphyric Attack: A Difficult Diagnosis for a Potential Lethal Event in Emergency Medicine by Cuoghi, Chiara et al.
*Corresponding author: Paolo Ventura, MD, Centre for Porphyrias - Division 
of Internal Medicine II, Department of Medical and Surgical Science for 
Children and Adults, University of Modena and Reggio Emilia, Policlinico Hospital 
of Modena, Largo del Pozzo 71, 41124 Modena MO, Italy, Tel: +39 594222807; 
Fax: +39 594224363; E-mail: paoloven@unimore.it
Citation: Cuoghi C, Marcacci M, Ventura P (2015) The Acute Porphyric Attack: 
A Difficult Diagnosis for a Potential Lethal Event in Emergency Medicine. J 
Emerg Med Trauma Surg Care 2: 005.
Received: October 22, 2014; Accepted: January 14, 2015; Published: January 
28, 2015
Introduction 
 The porphyrias are a heterogeneous group of rare metabolic 
diseases resulting from an inherited (in some circumstances the 
disturbance may be acquired) enzymatic deficiency in the pathway 
of heme biosynthesis (Figure 1). The enzymatic defect gives rise to a 
sort of metabolic ‘bottleneck’ in the biosynthetic pathway, which may 
result in an accumulation of metabolic intermediates (porphyrins 
and/or non porphyrin precursors) whose toxicity is responsible for 
the peculiar clinical pictures of these diseases [1-4]. In general, the 
porphyrias are classified as erythropoietic or hepatic, depending on 
the tissue where the metabolic defect is prevalent and thus on the site 
of major production of porphyrins and/or their precursors. These 
diseases are also classified as acute or non-acute, according to their 
main clinical features, even though the clinical manifestations may 
overlap in some forms [2,4-6].
 The clinical landmarks of the acute porphyrias are recurrent 
acute crisis (acute porphyric attack-APAs), characterized by a severe 
neuro-visceral involvement, expressing with abdominal pain, mental 
symptoms and potentially life-threatening acute neuropathy 
[2,5,7-11]. The non-acute porphyrias are characterized mainly by 
cutaneous manifestations related to photosensitivity (Table 1) 
[1,2,4,12-21]. It is to be remarked as all “acute” porphyrias are “hepatic” 
porphyrias, this suggesting the key-role of the liver in the pathogenesis 
of these diseases [6,7,15].
 The clinical features alone are not so specific and suitable to 
confirm a diagnosis of APA. For this reason, the knowledge and the 
correct interpretation of the appropriate tests are mandatory for an 
accurate clinical management of these diseases: a delayed diagnosis 
and/or an inappropriate treatment of an APA may be in fact fatal 
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Abstract
 The porphyrias are a heterogeneous group of metabolic 
disorders due to an inherited (but in some forms the disturbance may 
also be acquired) enzymatic deficiency in the metabolic pathway 
of heme biosynthesis. The variable degree of block in the heme 
biosynthetic pathway due to the enzyme deficiency results in 
accumulation of different metabolic intermediates, whose toxicity is 
responsible for the peculiar (cutaneous and/or neurovisceral) clinical 
pictures observed in each of these diseases. According to the clinical 
features, the porphyrias are classified as “acute” (or neuropsychic) 
[characterized by acute neurovisceral crises (the acute porphyric 
attack) involving the autonomic and/or central nervous system, but 
also the liver and the kidney] and “on acute” (or dermatological) 
(mostly presenting with cutaneous lesions, due to photosensitivity).
 The acute porphyrias are often misdiagnosed diseases: the acute 
porphyric attack may in fact mimic many other more common medical 
and neuropsychiatric conditions; its delayed diagnosis and treatment 
(or its inappropriate treatment) may result in a fatal outcome. For 
these reasons, many different specialists, such as surgeons, 
psychiatrists, gastroenterologists, neurologists, emergency 
physicians and dermatologists may be variably involved in the 
diagnostic process, especially in those cases presenting with 
acute and life-threatening clinical features. An early and definitive 
diagnosis is mandatory to improve outcomes and to assure that 
potentially harmful drugs are avoided. To date, the availability of an 
adequate treatment has significantly improved the outcome of the 
acute porphyric attacks, so the knowledge about the management of 
these events may be relevant for the physicians working in internal 
and emergency medicine units.
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Figure 1: Biosynthesis of Heme (enzymes and genes involved and correlated 
diseases are reported).
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[1,6,8,22-25]. In last decades, the availability of effective therapies 
(infusion-stable heme preparations) has significantly improved the 
outcome of APAs: for this reason, the knowledge about the diagnostic 
steps and the clinical management of these diseases is relevant, 
especially for the physicians working in internal and emergency 
medicine units [22,25-27].
 In this review, we propose some suggestions for diagnosing and 
managing an acute porphyric attack based on literature reviews and 
clinical experience of our centre, with long-time expertise in the 
clinical management of patients affected by porphyrias.
Material and Methods
 Studies and review articles related to Acute Porphyric Attack 
(APA) we referred in this review were sought via electronic databases 
(PubMed®, Medline®, Embase®) and were identified from key 
references within articles. Search terms and MeSH headings we used 
included the word crisis, acute attack, drugs, precipitating factors 
combined with each of the following: porphyrias, ala-synthase, haem, 
heme, haematin, haem arginate, acute intermittent porphyria, variegate 
porphyria, hereditary coproporphyria, ala-d deficiency porphyria, 
lead poisoning. Due to the matter of content, no formal evaluation of 
level of evidence was conducted in developing this narrative review.
The Acute Porphyrias: General Aspects and Notices 
of Epidemiology
 Heme synthesis proceeds through different and complex 
biochemical reactions, in turn catalysed by specific enzymes: 
succinyl-coenzyme A and glycine are progressively converted into 
the complex tetrapyrrole ring of protoporphyrin IX that, after 
complexation with an atom of Fe2++, leads to the formation of heme 
(Figure 1). A disturbance in the activity of each of these enzymes 
causes accumulation of different patterns of precursors, whose 
toxic effects are responsible for the different clinical pictures 
characterizing the porphyrias [1,3]. Four kinds of “porphyrias” may 
present with recurrent attacks of neuro-visceral symptoms (Acute 
Porphyric Attack- APA): for this reason they are also classified as 
“acute porphyrias” [6,7]. The most common of acute porphyrias is 
Acute Intermittent Porphyria (AIP) [28-30]. It has been reported 
that APAs characterizing AIP are clinically more severe, even though 
they are indistinguishable from those characterizing the other less 
common variants of acute porphyrias: Variegate Porphyria (VP) 
[3,31-34], Hereditary Coproporphyria (HCP) [3,5,35,36], and 
porphyria due to ALA dehydratase deficiency (ALAd-P) (which is 
extremely rare) [37]. Very similar clinical severe manifestations may 
also occur in case of lead poisoning, a condition also referred as 
plumboporphyria: it may be considered as an acquired disturbance of 
heme metabolism, being caused by the inhibition of ALA-dehydratase 
by lead [38,39].
 A reliable epidemiologic data collection about acute porphyrias is 
difficult due their low clinical penetrance: it is thought that less than 
10-15% (only about 1-3%, according to most recent data) of carriers 
of the enzymatic defect develops overt APAs [40-42]. Statistics about 
morbidity of acute porphyrias derive mostly from the experience of 
specialist porphyria centers [1,30], and from some systematic studies 
concerning each kind of porphyria from different countries 
[33,43-50]. The most recent prospective survey reports a similar 
incidence for AIP in all European countries [42] (ranging from 0.11 
to 0.22 per year per million, with an overall incidence of 0.12), with 
the significant exception of Sweden, where the incidence of about 
four-fold higher (0.51 per year per million) is probably explained 
by a “founder effect” [46]. For VP (about half that of AIP) and HCP 
(0.2 per year per 10 millions), the incidence in Europe is lower. In this 
study, the calculated overall prevalence of AIP in Europe (including 
Sweden) is about 5.9 per million inhabitants; it resulted significant-
ly lower with respect to previous estimates (from 10-20 per million 
to 101 per million), where probably all subjects with AIP, even those 
who never experienced symptoms, have been included [1,30,49,51]. 
Similar considerations are valid for the calculated European preva-
lence of VP (3.2 cases for million inhabitants) [42]; in South Africa, 
where a “founder effect” has been well-demonstrated, the genetic 
defect responsible for VP has an exceptionally high frequency (1:300) 
[52,53].
 To this regard, some retrospective studies have showed that in the 
last 50 years the number of symptomatic AIP patients (i.e. patients 
experiencing APAs) declined with time and this trend seemed to 
have continued subsequently [47,54]; similarly, a decrease in APA 
frequency in VP has been noted in South Africa [55]. Thus, this 
observed lower prevalence may also be consistent with a decreasing 
incidence of new acute attacks over the past decades, which could 
be explained by a significant improvement in diagnosis, treatment, 
family screening and preventive counseling. 
 In old studies, mortality during an APA has been reported to be 
as high as 50- 60% [56]. With modern treatment, however, APAs 
have rarely a lethal outcome. Nevertheless, according to an American 
report, the mortality rate was three times higher among patients 
with AIP, as compared to the general population, being symptoms 
associated with the APA itself the major cause of this increase in 
mortality [57].
The Acute Porphyric Attack: Clinical Pictures
 The clinical landmark of an acute porphyria is the Acute Porphyric 
Attack (APA). APA is characterized mostly by (recurrent) acute crisis 
with a severe neuro-visceral involvement, whose clinical expression 
may be greatly variable and able to mimic many other diseases 
(Table 2); for this reason, the acute porphyrias are often misdiagnosed 
diseases and many different specialists, such as surgeons, psychiatrists, 
gastroenterologists, neurologists and emergency physicians may be 
involved in the diagnostic process, especially in the cases presenting 
with very severe and life-threatening symptoms [58].
 An APA may be preceded by a period of minor behavioral changes 
such as restlessness, insomnia, anxiety and irritability: these 
symptoms may evolve rapidly to a severe autonomic and acute 
motor and sensory neuropathy. APAs may develop over hours or 
days and can last up to several weeks. The most common symptom 
of an APA is the onset of severe abdominal pain, usually described as 
excruciating by the patients and often suggesting an “acute abdomen” 
nevertheless the symptoms typically appear disproportionate with 
Acute Porphyrias
ALA dehydratase- deficiency Porphyria(ALAD-P)
Acute Intermittent Porphyria (AIP)
Hereditary Coproporphyria (HCP)
Variegate Porphyria (VP)
Non-Acute (Cutaneous) Porphyrias
Porphyria Cutanea Tarda (PCT)
Hepato-Erythropoietic Porphyria (HEP)* 
Erythropoietic Protoporphyria (EPP)
Congenital Erythropoietic Porphyria (CEP)
Table 1: Clinical classification of Porphyrias.
*homozygous variant of PCT
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respect to the physical examination (abdominal tenderness and main 
peritoneal signs are in fact usually absent). Back pain, often extending 
to the proximal limbs is also frequently present. The abdominal 
complaints are generally accompanied by gastroenteric (mostly 
nausea and vomiting, but also bowel distention, that may develop 
as an effect of paralytic ileus) and neurological and/or psychiatric 
symptoms. All components of the peripheral and of the central 
nervous system may be involved. A motor neuropathy, particularly 
a proximal motor neuropathy, is quite common in case of severe 
and prolonged attacks. Muscular weakness usually begins in the 
extremities of the limbs but can involve any motor neuron or 
cranial nerve: it can proceed to tetraplegia (resembling a Guillain- 
Barré syndrome). A bulbar involvement can proceed to respiratory 
failure [23,58]. Different grade of vegetative dysfunction (systemic 
arterial hypertension with postural arterial hypotension, tachycardia 
and constipation) may be also present [1,2].
 The involvement of central nervous system may be responsible 
for seizures and/or mental disturbances (varying from apathy and 
depression to extreme agitation, mimicking a psychotic attack with 
hallucinations) [10,11,59-63].
 Hyponatremia and hypomagnesemia may occur as a result of 
dehydration, nephrotoxicity, or also as an effect of excessive release 
of Antidiuretic Hormone (ADH) and/or inadequate endovenous 
administration of 10% or 20% glucose (or dextrose) solutions, a 
standard first-line therapy for APA  [64]. These water/electrolyte 
disturbances may contribute to the neurological and psychiatric 
symptoms of the APA. During an APA, urine appears often red or 
reddish-brown, as a consequence of massive excretion of porphyrins 
[6,58,65,66].
 In VP and HCP, a history (or the presence) of a photocutaneous 
syndrome, characterized by fragile skin and bullous eruptions 
exclusively interesting the sun-exposed areas (the lesions typically 
occur on the dorsal aspects of the hands and forearms, the face, ears, 
and neck), may be present [3,58].
 APAs have been rarely described before puberty, with a peak age 
of presentation in the early 30s, and they are four-to-five times more 
common in women than in men [2,3,67]. In most people, the disease 
may remain latent throughout life even in the presence of precipitating 
factors: it has been estimated that only 10-15% (according to more 
recent data less than 3%) of gene carriers of an acute porphyria may 
experience an APA throughout their lifetime [6,41,50,66,68,69]. At least 
one third of these symptomatic patients have often no family history, 
this suggesting a condition remained latent or unidentified for 
several generations. Also the frequency and severity of APAs have 
a great variability: some patients experience frequent, severe and 
sometimes life-threatening attacks, even in the absence of exogenous 
precipitating factors [6]. Nevertheless, in most cases, an APA is 
precipitated by one or more “triggering factors”, such as drugs, changes 
in hormone balance (as during menses or hormonal therapies), local 
or general anesthesia, sedative use (especially barbiturates), misuse 
of alcohol or illicit substances (amphetamines, cocaine and other 
derivatives), prolonged fasting or diet restrictions, intense mental or 
physical stress, or acute infections [1,2,6,70]. In women, recurrent 
attacks often coincide with the luteal phase of the menstrual cycle 
[71]. APAs have been described also during pregnancy, coinciding 
with high estrogen concentrations: for this reason, the symptomatic 
patients should be advised to avoid pregnancy until remission 
has been present for at least 2 years; nevertheless in most cases, 
pregnancy is symptom-free. On the contrary, particular attention 
Signs/symptoms of APA %
Conditions mimicked by APA
Surgical 
Conditions
Hematological 
conditions
Gastroenterologi-
cal conditions
Cardiovascular 
conditions
Dismetabolic/
Disendocrine  
conditions
Neurologic
and psychyatric 
conditions
(Severe) abdominal pain 95-97
-Peritonitis
-Appendicitis
-Acute pancreatitis and 
cholecystitis
-Intestinal ischemia
-Acute hemolytic 
crisis
-Acute drepanocyt-
ic crisis
-Paralytic Ileus
-Acute pancreatitis 
-Acute chole-
cystitis
Nausea, Vomiting                                      
Constipation                                               
48-85 
46-52
-Acute gastro-
enteritis with 
vomiting
Tachycardia                                                           
Hypertension (diastolic>85 
mmHg)           
Chest pain
65-80 
38-64 
8-15
-Hypertensive 
crisis
-Tachyarrhyth-
mia
-Acute Coro-
nary Syndrome
-Pheocromocy-
toma
Hypotension                                                          
Hyponatriemia
(<120 mEq/L)
15-22 
25-35
-Acute hypoad-
renalism (Addiso-
nian crisis)
-SIADH
Peripheral motor -neuropathy
Sensory neuropathy
Hypo/areflexia
Back pain
Seizures
Coma
40-60
20-28
20-30
20-30
10-20
2-10
-Acute hypopara-
thyroidism (hypo-
calcemic crisis)
-Acute hyperpara-
thyroidism and 
other hypercalce-
mic conditions
-Guillain–Barre` 
syndrome
-Idiopathic/ meta-
bolic autoimmune
-Polineuropathies
-Emicrania
-Epilepsy
-Acute myopathies
Mental changes/psychosis 10-40
-Acute psychotic 
attack
-Delirium
-Acute panic attack
Table 2: Signs and symptoms of Acute Porphyric Attack (percentage indicate the frequency)* and conditions that may frequently mimicked by APA.
*NB More symptoms may be present contemporary during an APA. Modified from refreneces 1,2,3,13,25,40,50,54.
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should be payed at the delivery and post-delivery periods: they 
represent in fact important precipitant conditions (stress, blood losses, 
starvation, etc.) and a high frequency of APAs has been described 
throughout. If APAs do occur during pregnancy or in the immediate 
post-delivery period, they should be treated as is customary  [72,73].
The Acute Porphyric Attack: Associated Pathologic 
Conditions
 Different epidemiological studies have suggested a significant 
correlation between AIP, arterial systemic hypertension and kidney 
disease. Hypertension has often been described as well in HCP 
and VP, but the incidence of renal involvement in these conditions 
remains ill-defined with respect to that observed in AIP. The 
treatment of arterial hypertension decreases the risk for renal 
impairment in carriers of a gene mutation consistent with a form of 
acute porphyria; symptomatic patients should carefully be managed 
through regular monitoring of blood pressure and renal function 
[74,75]. Severe and recurrent motor involvement during APAs may 
lead to persistent muscle weakness and atrophy [10]. A significant 
association between acute porphyrias and Hepatocellular Carcinoma 
(HCC) has also been described: 27% of patients carrying the W198X 
mutation of the porphobilinogen-deaminase gene are reported to be 
affected by HCC in a mortality study [76,77]. Cirrhosis, hepatocellular 
carcinoma, systemic arterial hypertension, and renal impairment have 
been reported as more common after middle age in AIP and possibly 
also in VP and HCP, especially in symptomatic patients [78].
The Acute Porphyric Attack: Physiopathology and 
Precipitating Factors
 The pathophysiologic mechanisms underlying the clinical features 
of APAs are still poorly understood; possible mechanisms include: 
a. Damage by free radicals formed as a consequence of porphyrin 
and/or porphyrin praecursors accumulation (not completely 
confirmed) [79].
b. A direct neurotoxicity of the accumulating porphyrin precursor 
Delta-Aminolevulinic Acid (ALA) [80-82].
c. An acute heme deficiency in nervous and other tissues [83,84].
 It has been demonstrated that ALA is neurotoxic [82,85]. The 
blood-brain barrier protects the brain from toxic agents, but certain 
areas such as the hypothalamus and limbic area do not have 
such protection [10]. Moreover, circulating porphyrins and their 
precursors can cause vascular injury, leading to impaired 
permeability, and resulting in reversible focal edema in the brain 
[10]. The autonomic and peripheral nervous systems are especially 
vulnerable to this toxic action, due to absence of a specific barrier 
protection. Vulnerability of neurons to toxic reactions seems to 
be highly variable among individuals: this may explain why some 
patients are more prone to paresis than others are. Some patients 
affected by acute porphyria have constantly elevated levels of 
porphyrins and their precursors also during the symptom-free phase, 
but even their excretion level increases during an acute attack [65,68]. 
ALA has also been suggested as a carcinogenic for the liver [76]; it can 
cross the placenta and possibly cause toxicity to the developing fetal 
brain [73].
 From a biochemical point of view, the landmark of the APA 
is the significant accumulation of the non-porphyrin precursors 
Delta-Aminolevulinic Acid (ALA) and Porphobilinogen (PBG) in 
biological fluids, as an effect of their excessive liver production due 
to induction of heme biosynthesis [2,3]. The synthetic rate of heme 
depends mostly on the current activity of the first enzyme of the chain, 
5-Aminolevulinate Synthetase (ALA-S1) (a rate-limiting step) (Figure 
1). ALA-S1 activity is feedback-governed by the amount of free heme 
present within the cell (the hepatocyte). A decrease in the availability 
of this “regulatory” free heme pool gives rise to ALA-S1 induction, 
and hence to an increase of heme biosynthesis [86]. A second rate- 
limiting enzymatic reaction is the third step of heme synthesis 
[catalyzed by Porphobilinogen Deaminase (PBG-D)]. In contrast to 
ALA-S step, which represents a variable control step for the synthetic 
process, the constantly limited capacity of the PBGD (HBMS) 
step functions as a sort of “inbuilt safety-valve” regulating the 
overproduction of toxic porphyrins along the biosynthetic chain. 
In the acute porphyrias, the enzymatic activity of PBGD (HBMS) is 
significantly compromised: 
1. As a consequence of a genetically determined deficiency in case 
of AIP; 
2. Probably as an inhibitory effect by porphyrins produced in surplus 
in case of VP and HCP.
 The restoration of a normal porphyrin metabolism in an AIP 
symptomatic patient (who thereafter became attack-free) after 
liver transplantation, confirms the key role of the liver as a source of 
non-porphyrin precursors in acute porphyrias [87,88]. Exogenous 
and endogenous factors able to induce the expression and/or the 
activity of ALA-S1 (as in the case of drugs or pathological conditions 
reducing the free heme pool) are well-known potential triggering 
factors of APAs [1-3,70]. 
The Acute Porphyric Attack: Diagnosis and Differen-
tial Diagnosis
 The correct and prompt diagnosis of an APA greatly depends 
on the awareness, the knowledge and experience of the clinician: 
misdiagnosis is common, because the APAs may be easily confused 
with other causes of acute abdomen (sometimes leading to 
unnecessary surgery) or with primary neurologic or mental diseases. 
The probability of APA being present may be higher when the patient 
can report that he/she is a member of porphyria kindred, or he/
she is actually a carrier of genetic mutations consistent with acute 
porphyria, in the best case verified by a personal warning card, issued 
by the specialist responsible for the diagnosis [89]. Emission of dark 
(red or reddish brown) urine, in correspondence of symptoms onset, 
is a cardinal sign and it is often present during APA [58,90-92]. 
 As already remarked above, it should be noted that universal signs 
or symptoms of APA do not exist, and in up to 5%-10% of patients the 
disease may express without the most widespread and shared features 
(such as the severe abdominal pain) [59,93]. A family history may 
be relevant in the presence of symptomatic relatives, but it may also 
be inconclusive as the acute porphyrias are diseases characterized by 
highly incomplete penetrance and most carriers may remain life-long 
asymptomatic. On the other hand, it is recommendable to test 
immediately patients with abdominal pain and/or other suggestive 
findings of APA and a family history of acute porphyria [6,58,90,92]. 
When a patient known to be affected by acute porphyria shows 
symptoms consistent with APA, the further question is whether 
the clinical picture is due to its disease or not: not all symptoms in 
porphyric patients are due to APA; moreover, patients with acute 
porphyrias may be suffering from other (and more common) 
diseases. Table 2 summarizes some of the most common pathological 
conditions whose differential diagnosis should include an APA.
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 Due to their non-specificity, the clinical features alone are not 
sufficient either to confirm a diagnosis of APA or to differentiate 
between the different forms of acute porphyria. For this reason, 
an immediate (we recommend simultaneously at the onset of 
symptoms) assessment and interpretation of some appropriate 
laboratory biochemical tests (i.e. determination and quantification 
of porphyrins and non-porphyrin precursor patterns in biological 
samples) are mandatory for an accurate diagnosis, and for starting 
an appropriate clinical management [3,25,58,90-92,94,95]. According 
to current knowledge and consensus, an APA is invariably 
associated with an increased urinary excretion of non-porphyrin 
precursors [ALA and PBG] [6,25,92,96,97] (Figure 2). For this 
reason, in case of suspected APA, a fresh light-protected urine sample 
should be assessed for ALA and PBG concentrations [to date, 
HPLC assays are the most accurate, but rapid, ion-exchange column 
tests (column-chromatographic screening tests) are also available] 
(first-line test) [66,98-102]. In case of significant renal dysfunction, 
ALA and PBG levels should be assessed in serum [102].
 Different Ehrlich’s reagent-based tests (such as the 
Watson-Schwartz test or the Hoesch test, where the colourless 
pyrrole PBG forms a red-violet pigment after reaction with 
p-dimethylaminobenzaldehyde) may be used as a rapid assay 
(“bed-side” assessment) to test the presence of urinary PBG 
(qualitative test) [103,104]. These tests may be considered a “first-line” 
guide to confirm (or to rule-out) a suspicion of APA, if made at or 
near the time of the clinical onset in case of the most common acute 
porphyrias (AIP, PV and HCP). They may miss the diagnosis in some 
extremely uncommon circumstances (false positive and/or negative 
results): 
a. Subjects affected by the rare ALAd-D porphyria or by lead- 
poisoning, two disorders being characterized by accumulation of 
ALA, but not of PBG; 
b. Subjects immediately treated with heme arginate (which rapidly 
decreases ALA and PBG); 
c. In some cases of HCP and VP, where the increase in ALA and PBG 
levels may be more transient, as well the corresponding symptoms; 
d. In cases of high urinary bilinogen excretion (due to possible 
cross-reaction with p-dimethylaminobenzaldehyde) [97,105].
 During an APA, especially in case of AIP, urinary ALA and PBG 
are generally very high, so that potential differences in reference 
ranges among different laboratories are of little relevance, as well the 
collection of urine samples for 24 hours, which may contribute to 
delay the diagnosis. The classical 24-hour urine collection approach 
has been recently replaced by the assessment on spot urine sample, 
in which the ALA and PBG values are normalized on urinary 
creatinine. In the presence of suspected symptoms, PBG and ALA 
levels higher than 5 times the normal range indicate an APA 
[58,90,106]. It should be recommended that all major medical 
facilities and emergency units are provided at least for in-house 
rapid determination of urinary PBG levels [preferably by using rapid 
(“bedside”) test kits], because a significant delay in diagnosis may be 
responsible for potential fatal consequences of delayed treatments. If 
urinary PBG levels are increased, further testing will determine the 
definite disorder of heme metabolism, although treatment (which 
is the same regardless of the type of acute porphyria) should never 
be delayed, waiting for these results [58]. If only the ALA level is 
substantially increased, ALA-dehydratase porphyria and other 
causes of ALA-dehydratase deficiency, such as lead poisoning 
(plumboporphyria) or hereditary tyrosinemia type 1 should be taken 
into account before starting treatment [3,7,92,97,107,108]. If urinary 
PBG and ALA levels are normal, an alternative diagnosis to APA 
must be considered. In our experience, urinary ALA and PBG values 
significantly decrease with clinical improvement and dramatical-
ly after therapy (especially after heme arginate infusion) (Figure 2). 
Urinary ALA and PBG levels are generally less markedly increased 
in APAs due to HCP and VP and they decrease more rapidly after 
an acute attack than in AIP [34,58]. Because treatment of APA does 
not depend on the type of acute porphyria, the identification of the 
specific kind of acute porphyria is important mainly for a correct 
diagnosis, for finding the gene carriers among relatives and 
counseling [58,92]. In the absence of a family history, the different 
forms of acute porphyria may be distinguished by the characteristic 
patterns of porphyrin (and porphyrin-precursors) accumulation and 
excretion in plasma, urine, and stool. In case of increased urinary 
levels of ALA and PBG, fecal porphyrins should be measured: they are 
usually normal or minimally increased in AIP but elevated in HCP 
and VP [106]. It is worth reminding that some of these markers may 
be not present in the latent phase of the disease. Plasma fluorescence 
emission after excitation within the Soret band of light (at 410 nm 
of bandwidth) can be used to differentiate HCP and VP, which are 
Figure 2: Schematic algorithm for diagnosis of Acute Porphyric Attack (APA).
Unfortunately, the “bedside” assessment (qualitative) for urinary PBG is not 
everywhere available yet; so urinary PBG (and ALA) are still often simultane-
ously measured (qualitatively and quantitatively) as first-line assays (by HPLC 
or column-chromatographic test).
*Considering the extreme rarity of ALA dehydratase-deficiency porphyria 
(ALAD-P, which is characterized mostly by a greater ALA increase), the posi-
tivity of the “bedside” PBG assay, together with compatible clinical features, is 
highly suggestive of diagnosis of APA.
In case of “bedside” PBG test negative, the laboratory assessments for ALA 
and PBG may be relevant to rule out conditions characterized only by ALA 
increase (lead poisoning, ALAD-P or tyrosinemia).
**Check for ALAD-P; rule out tyrosinemia and lead poisoning.
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characterized by different peak emissions [2,3,92,106,109]. Red blood 
cells activity of ALA-dehydratase and PBG-deaminase (Hydroxymeth-
yl-bilane Synthase-HBMS) may be also readily assessed and can be 
helpful for establishing the diagnosis in ALAd-D porphyria and AIP, 
respectively [58]. Genetic testing may be helpful in the definitive 
diagnosis, especially when the type of disease and mutation are not 
already known from previous testing of relatives [58,110]. At present, 
accurate genotype-phenotype correlation for acute porphyrias is still 
ill-defined. Nevertheless, it is known the some types of gene mutations 
[such as Q180X, 198X and R173W mutations in PBGD (HBMS) gene, 
responsible for AIP, or R59W mutation in PPOX gene, responsible for 
VP] are associated with a significant higher penetrance of the diseases 
[52,53,111,112].
The Acute Porphyric Attack: The Treatment
 The treatment of APA is the same apart from the kind of 
underlying acute porphyria (Table 1). Identification and elimination 
of all possible trigger factors (ex: drugs, infections and alcohol abuse) 
are mandatory. Except in the case of mild attacks, most patients 
require hospitalization and a continuous monitoring of neurologic 
status, blood pressure, heart rate, fluid and electrolyte balance, muscle, 
tendon and respiratory function. Symptoms (ex: systemic arterial 
hypertension, vomiting, seizures) should be treated avoiding 
porphyrinogenic drugs [7,25,70,92]. Opiates should be considered as 
mandatory in pain management during APA, being careful to prevent 
the opioid dependence in case of prolonged use [3,25].
 Glucose down-regulates liver ALA-S (ALA-S1) (and hence ALA 
and PBG accumulation) and may help in resolving the crisis [113,114]. 
It can be administered by mouth in absence of nausea or vomiting, 
but, in most cases, it is given intravenously: the suggested regimen is 
2-3 L of 10%-20% glucose (or dextrose) solution, infused by a central 
venous catheter over 24 h (100-125 mL/h). During the infusion 
period, it is important to carefully monitor the patient’s blood 
parameters, in order to avoid over hydration and/or electrolyte 
imbalance (especially hyponatremia) [3,25,92,115].
 Heme infusion is much more effective than glucose in down- 
regulating ALA-S1 and should be used immediately in case of severe 
painful attacks, electrolyte imbalance or neurological involvement. It 
has been observed that in case of significant neuropathic involvement, 
a delay in heme infusion may be responsible for more severe nerve 
damage and a slower and possibly incomplete recovery of neuropathy 
[25]. 
 In most cases, heme infusion resolves the APAs in 2-4 days. In 
U.S. heme is available as lyophilized hematin (Panhematin®), to be 
reconstituted with sterile water [116]. In Europe, heme is available as 
heme arginate (Normosang®) solution, to be diluted in 5% glucose or 
saline. In both cases, the recommended dose is 3 to 4 mg/kg IV once/
day for 3-4 days [25,92,115-118]. Both hematin and heme arginate 
infusion may cause venous thrombosis and/or thrombophlebitis. 
Risk of these adverse events appears to be reduced if the heme is 
administered together with human serum albumin. Such binding also 
decreases the rate of development of hematin aggregates and improve 
the heme delivering to the tissues. For this reason, most experts 
recommend the infusion of heme (hematin or heme arginate) in 
association with human serum albumin [25,115]. In patients affected 
by severe forms of acute porphyrias (severe and recurrent attacks), 
who are considered at higher risk of kidney impairment or permanent 
neurologic damage, liver transplantation may be an option. Successful 
liver transplantation leads to permanent cure of all acute porphyrias. 
Patients with acute porphyrias should not serve as liver donors even 
though their liver may appear structurally normal (i.e., no cirrhosis), 
because recipients have developed APAs; such an outcome 
helped to confirm that the acute porphyrias are hepatic disorders 
[87,88,119-121]. Renal transplantation, with or without simultaneous 
liver exchange, should be considered in patients with active disease 
and terminal renal failure, because there is considerable risk that 
nerve damage will progress at the start of dialysis. The good results of 
recent experimental trials, based on gene-therapy approaches, depict 
new promising opportunities for the treatment of acute porphyrias, 
even in acute conditions [122-124].
The Acute Porphyric Attack: The Prevention
 All the people identified as carriers of an acute porphyria should 
carry a card attesting the carrier state and the precautions to be 
observed. The role of drugs in precipitating porphyric attacks, due to 
their possible effect on heme metabolism, is well-established; any drug 
treatment for a patient with porphyria should be prescribed according 
to an accurate reference to a drug list [3,20,70,125]. This is particularly 
important in surgery, many anesthetics being well-known powerful 
precipitant factor of acute attack [1,13,70,126,127]. Complete lists 
of potentially safe and unsafe drugs are continuously upgraded, and 
they are available on the net, at http://www.drugs-porphyria.org/ and 
http://www.porphyria-europe.com [89,128]. Some drugs are strictly 
forbidden, due to their well-depicted association with great number 
of severe attacks, however, most drugs are considered only potentially 
dangerous, and the majority of patients often tolerate them. For this 
last group of drugs, a common sense assessment of benefit versus risk 
is needed; an acute attack is in fact less likely to be precipitated in 
case of latent disease, or if the patient has experienced only a single 
attack, or if the concentrations of urinary metabolites (PBG, and 
particularly ALA) are within the normal range at the time of the 
prescription [7,70]. Alcohol abuse should be strictly forbidden, due 
its well-known effect in inducing heme metabolism. Due to the effect 
of glucose on heme metabolism, prolonged periods of starvation or 
drastic diets should be avoided: on the contrary a high-carbohydrate 
diet may decrease the risk and the frequency of acute attacks [3,7].
 Patients who experience recurrent and predictable attacks 
(typically, women with attacks related to the menstrual cycle) may 
benefit from prophylactic heme therapy given shortly before the 
expected onset. No maintenance-standardized regimen is available: 
a specialist should be consulted [3,25,115]. Frequent premenstrual 
attacks in some women are aborted by administration of a 
gonadotropin-releasing hormone agonist plus low-dose estrogen. 
Low-dose oral contraceptives are sometimes used successfully, but the 
progestin component is likely to exacerbate the porphyria [129].
 To prevent renal damage, chronic systemic arterial hypertension 
should be treated aggressively (using safe drugs). Patients with 
evidence of impaired renal function should be referred to a 
nephrologist. Due the defined higher risk for hepatocellular 
carcinoma, patients affected by acute porphyria should undergo twice- 
yearly surveillance, including liver screening with ultrasonography 
[7,78,130].
Conclusion
 The acute porphyrias are rare diseases but their clinical 
exacerbations (acute porphyric attacks) may be potentially lethal 
conditions, especially if misdiagnosed or inappropriately treated.
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 The clinical features alone are not so specific and suitable to 
confirm a diagnosis of APA: for this reason, the knowledge and the 
correct interpretation of the appropriate tests are mandatory for an 
accurate clinical management of these diseases. In last decades, the 
availability of infusion-stable heme preparations has significantly 
improved the treatment outcome of APAs: for this reason, the 
knowledge about the diagnosis and the management of these diseases 
is relevant, especially for physicians working in internal and 
emergency medicine units. 
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